Prior view was $2.1B-$2.2B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- NBIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Neurocrine launches Ingrezza capsules for dysphagia
- Neurocrine price target raised to $170 from $160 at Morgan Stanley
- Neurocrine price target raised to $173 from $169 at JPMorgan